{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:26:03Z","timestamp":1787739963959,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10067-013-2478-x","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T09:42:27Z","timestamp":1389001347000},"page":"531-536","source":"Crossref","is-referenced-by-count":26,"title":["Open-label study on treatment with 20\u00a0% subcutaneous IgG administration in polymyositis and dermatomyositis"],"prefix":"10.1007","volume":"33","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"issue":"344\u20137","key":"2478_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292(344\u20137):403\u2013407","journal-title":"N Engl J Med"},{"issue":"3","key":"2478_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","volume":"11","author":"MC Dalakas","year":"2012","unstructured":"Dalakas MC (2012) Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 11(3):203\u2013206","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2478_CR3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10(3):144\u2013149","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2478_CR4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/imt.10.108","volume":"3","author":"M Berger","year":"2011","unstructured":"Berger M (2011) L-proline-stabilized human IgG: Privigen\u00ae 10\u00a0% for intravenous use and Hizentra\u00ae 20\u00a0% for subcutaneous use. Immunotherapy 3(2):163\u2013176","journal-title":"Immunotherapy"},{"key":"2478_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Trembaly JL et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231\u2013249","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2478_CR6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s10875-011-9557-z","volume":"31","author":"M Borte","year":"2011","unstructured":"Borte M, Pac M, Serban M et al (2011) Efficacy and safety of Hizentra\u00ae, a new 20\u00a0% immunoglobulin preparation for subcutaneous administration, in paediatric patients with primary immunodeficiency. J Clin Immunol 31(5):752\u2013761","journal-title":"J Clin Immunol"},{"issue":"Suppl1","key":"2478_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2009.04028.x","volume":"158","author":"E Fernandez-Cruz","year":"2009","unstructured":"Fernandez-Cruz E, Kaveri SV, Peter H-H et al (2009) Intravenous immunoglobulin in immunodeficiencies and autoimmunity. Clin Exp Immunol 158(Suppl1):60\u201367","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2478_CR8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","volume":"16","author":"SA Misbah","year":"2011","unstructured":"Misbah SA, Baumann A, Fazio R et al (2011) A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 16(2):92\u201397","journal-title":"J Peripher Nerv Syst"},{"issue":"27","key":"2478_CR9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993\u20132000","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"2478_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","volume":"38","author":"S Kivity","year":"2010","unstructured":"Kivity S, Katz U, Daniel N et al (2010) Evidence for the use of intravenous immunoglobulins\u2014a review of the literature. Clin Rev Allergy Immunol 38(2\u20133):201\u2013269","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"2478_CR11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/rheumatology\/keq021","volume":"49","author":"PM Vaitla","year":"2010","unstructured":"Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology 49(6):1040\u20131048","journal-title":"Rheumatology"},{"issue":"6","key":"2478_CR12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","volume":"7","author":"JF Seite","year":"2008","unstructured":"Seite JF, Shoenfeld Y, Youinou P, Hillion S (2008) What is the content of the magic draft IVIg? Autoimmun Rev 7(6):435\u2013439","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2478_CR13","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","volume":"179","author":"A Kessel","year":"2007","unstructured":"Kessel A, Ammuri H, Peri R et al (2007) Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179(8):5571\u20135575","journal-title":"J Immunol"},{"issue":"1","key":"2478_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","volume":"141","author":"S Jolles","year":"2011","unstructured":"Jolles S, Bernatowska E, de Gracia J et al (2011) Efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 141(1):90\u2013102","journal-title":"Clin Immunol"},{"issue":"1","key":"2478_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","volume":"23","author":"A Martin","year":"2013","unstructured":"Martin A, Lavoie L, Goetghebeur M, Schellenberg R (2013) Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 23(1):55\u201360","journal-title":"Transfus Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2478-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2478-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:30Z","timestamp":1559120250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2478-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2478-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]}}}